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Treatment of some specific deadly diseases are becoming 
more robust in these days, cancer and psychosis are two 
most lethal diseases among them. Sometimes, the 
chemotherapeutic drugs become to be impassable through 
the intercellular membrane or the affected cells become 
multidrug resistant. To minimize these issues, the 
introduction of nanoparticles is the only way out. 
Introduction of nanoparticles with the chemotherapeutic 
drug is not only helping to detect the disease at an early 
stage but also making sure the speedy recovery of the 
patient1-15. Hence, nanoparticles are used as the prime 
ingredient in the chemotherapeutic drug incorporated into 
the human body.   
Nanoparticles are getting used in numerous ways to get the 
maximum positive impact from the drug. To get proper 
treatment in lung cancer cases therapeutic delivery of 
antimiR-21 is very much necessary, but sometimes it 
becomes impossible for anti-miR to control the cell 
overexpression16-29. Therefore, nanoparticles are 
incorporated with the anti-miR to get the most positive 
impact to stop the cell and gene overexpression. Lipid 
nanoparticles get conjugated with a quaternary amine to 
make the most effective anti-miR drug to cure lung cancer. 
On the other hand, lung cancer can get healed by another 
process of dual modulation of Bcl-2 and Akt-1. In the later, 
one lipid nanoparticles get conjugated with T7 peptide.  
This strategy is mainly used to induce RNase H cleavage. 
Deoxynucleotide monomers are mostly used to build the 
central block of the chimeric anti-sense oligonucleotide. 
According to Gapmer strategy, the antisense nucleotides 
(ASO) get their 2-O-methyl modification in 5 and 3 ends. 
Apart from lung cancer, this process is getting used 
successfully for the cure and recovery of cervical cancer as 
well. Along with it, the process of DNA methylation and 
histone modification are few such processes that are 
working correctly to minimize the actual issues30-40.  
Doxorubicin (DOX) is one of the most effective therapeutic 
drugs that are mostly used liposomal doxorubicin. To 
ensure the active delivery of the liposomal doxorubicin 
peptide-based ligands is used.  
As a result of “Gapmer strategy” increases the efficacy of 
the therapeutic drug administered into the patient’s body. 
In the process of DNA methylation, the formation of local 
heterochromatin gets facilitated, and thus the cancerous 
cell propagation gets hindered. The method of DNA 
methylation and histone modification takes place at the 
same time because the processes are interdependent to 
each other. Doxorubicin (DOX) gets used mainly for the 
treatment purpose of malignant tumors. Leukemia and 
Hodgkin’s Leukemia is such a malignant tumor that usually 
gets treated by DOX. The PEGylated liposome is unable to 
actively target the cancerous cells in spite of getting carried 
through the intercellular membranes of the human body41-
47. The incorporation of nanoparticles with it increases its 
capacity to transport the toxin parts into the tumor cells. To 
get the peptide ligand incorporation, some specific 
materials are used as the peptide base. Antibodies, 
proteins, small molecules are mainly used as those 
peptides. The cause of using these peptide ligands is the 
low cost, enzymatic degradation, and easy availability. 
Apart from this, the easy preparation procedure of these 
peptide ligands is another reason to choose them for the 
cancerous cell targeting agent48-51.  
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Figure 1: Gapmer Strategy23.  
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